Marco Sgarbanti

List of Publications by Year in descending order

35 papers	1,035 citations	471061 17 h-index	414034 32 g-index
38 all docs	38 docs citations	38 times ranked	1492 citing authors

#	Article	IF	Citations
1	HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators. Oncogene, 2001, 20, 800-811.	2.6	198
2	Modulation of Human Immunodeficiency Virus 1 Replication by Interferon Regulatory Factors. Journal of Experimental Medicine, 2002, 195, 1359-1370.	4.2	102
3	IRF-1 Is Required for Full NF-ÎºB Transcriptional Activity at the Human Immunodeficiency Virus Type 1 Long Terminal Repeat Enhancer. Journal of Virology, 2008, 82, 3632-3641.	1.5	83
4	HIV-1 Latency: An Update of Molecular Mechanisms and Therapeutic Strategies. Viruses, 2014, 6, 1715-1758.	1.5	61
5	Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines. Oncogene, 2003, 22, 964-973.	2.6	48
6	Review: IRF Regulation of HIV-1 Long Terminal Repeat Activity. Journal of Interferon and Cytokine Research, 2002, 22, 27-37.	0.5	43
7	A requirement for NF-ÎºB induction in the production of replication-competent HHV-8 virions. Oncogene, 2004, 23, 5770-5780.	2.6	38
8	HIV-1, interferon and the interferon regulatory factor system: An interplay between induction, antiviral responses and viral evasion. Cytokine and Growth Factor Reviews, 2012, 23, 255-270.	3.2	38
9	IÎºB Kinase Îµ Targets Interferon Regulatory Factor 1 in Activated T Lymphocytes. Molecular and Cellular Biology, 2014, 34, 1054-1065.	1.1	33
10	Type I Interferons in COVID-19 Pathogenesis. Biology, 2021, 10, 829.	1.3	32
11	Role of Acetylases and Deacetylase Inhibitors in IRF-1-Mediated HIV-1 Long Terminal Repeat Transcription. Annals of the New York Academy of Sciences, 2004, 1030, 636-643.	1.8	31
12	Therapeutics for HIV-1 reactivation from latency. Current Opinion in Virology, 2013, 3, 394-401.	2.6	30
13	Interferon regulatory factorâ€1 acts as a powerful adjuvant in tat DNA based vaccination. Journal of Cellular Physiology, 2010, 224, 702-709.	2.0	27
14	IRF-7: New Role in the Regulation of Genes Involved in Adaptive Immunity. Annals of the New York Academy of Sciences, 2007, 1095, 325-333.	1.8	24
15	Human Papillomavirus Type 16 E5 Protein Induces Expression of Beta Interferon through Interferon Regulatory Factor 1 in Human Keratinocytes. Journal of Virology, 2011, 85, 5070-5080.	1.5	24
16	Type I IFN â€“ A blunt spear in fighting HIV-1 infection. Cytokine and Growth Factor Reviews, 2015, 26, 143-158.	3.2	22
17	Alternate NF-ÎºB-Independent Signaling Reactivation of Latent HIV-1 Provirus. Journal of Virology, 2019, 93, .	1.5	20
18	HIV-1 Tat Recruits HDM2 E3 Ligase To Target IRF-1 for Ubiquitination and Proteasomal Degradation. MBio, 2016, 7, .	1.8	19

#	Article	IF	Citations
19	The design of optimal therapeutic small interfering RNA molecules targeting diverse strains of influenza A virus. Bioinformatics, 2011, 27, 3364-3370.	1.8	18
20	IFN Regulatory Factors and Antiviral Innate Immunity: How Viruses Can Get Better. Journal of Interferon and Cytokine Research, 2016, 36, 414-432.	0.5	18
21	The development of immune-modulating compounds to disrupt HIV latency. Cytokine and Growth Factor Reviews, 2012, 23, 159-172.	3.2	17
22	Development and Validation of a Novel Dual Luciferase Reporter Gene Assay to Quantify Ebola Virus VP24 Inhibition of IFN Signaling. Viruses, 2018, 10, 98.	1.5	17
23	On the Role of Interferon Regulatory Factors in HIV-1 Replication. Annals of the New York Academy of Sciences, 2003, 1010, 29-42.	1.8	16
24	Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators. Journal of Virology, 2019, 93, .	1.5	16
25	CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats. Journal of Virology, 2021, 95, e0135821.	1.5	13
26	Fighting HIV-1 Persistence: At the Crossroads of â€œShoc-K and B-Lockâ€• Pathogens, 2021, 10, 1517.	1.2	12
27	Analysis of the Signal Transduction Pathway Leading to Human Immunodeficiency Virus-1-Induced Interferon Regulatory Factor-1 Upregulation. Annals of the New York Academy of Sciences, 2004, 1030, 187-195.	1.8	11
28	ÎºB kinase-Îµ-mediated phosphorylation triggers IRF-1 degradation in breast cancer cells. Neoplasia, 2020, 22, 459-469.	2.3	8
29	HIV-1 targeting of IFN regulatory factors. Future Virology, 2011, 6, 1397-1405.	0.9	7
30	Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy. Pathogens, 2021, 10, 1488.	1.2	5
31	IRF-7: an antiviral factor and beyond. Future Virology, 2013, 8, 1007-1020.	0.9	3
32	Generation of a human immunodeficiency virus type 1 chronically infected monkey B cell line expressing low levels of endogenous TRIM5Î±. Journal of Cellular Physiology, 2009, 221, 760-765.	2.0	1
33	190 IRF-1 is required for full NF-ÎºB transcriptional activity at the HIV-1 LTR enhancer. Cytokine, 2008, 43, 284.	1.4	0
34	CS03-5. IRF-1 phosphorylation by I-kappa-B kinase epsilon impairs IFN beta stimulation in activated CD4+ T cells.. Cytokine, 2011, 56, 9.	1.4	0
35	A model of the three-dimensional structure of human interferon responsive factor 1 and its modifications upon phosphorylation or phosphorylation-mimicking mutations. Journal of Biomolecular Structure and Dynamics, 2019, 37, 4632-4643.	2.0	0